The laboratory and animal study suggests that the substance interleukin 21 (IL-21) might improve the effectiveness of the drug Herceptin. The findings suggest that this happens because the IL-21 boosts the cancer-killing activity of immune cells called natural killer (NK) cells, which attack the tumor.
The findings by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are published in the July 1 issue of The Journal of Immunology. The researchers hope to begin a clinical trial to test the strategy in humans soon.
Herceptin is used to treat HER2-positive breast cancer -- about 20 percent of all breast-cancer cases. HER2 breast cancers have a protein called HER2 on the surface of the tumor cells. Herceptin attaches to the HER2 protein and coats the cells.
The findings indicate that IL-21 stimulates NK cells to attack and destroy the Herceptin-coated cells.
“Only 25 to 35 percent of patients with this form of breast cancer respond to Herceptin,” says principal investigator William E. Carson, III, associate professor of surgery and associate director for clinical research at the OSU Comprehensive Cancer Center .
“Our results suggest that giving IL-21 along with the Herceptin might increase the patient's immune response to the tumor and perhaps boost the drug's effectiveness.”
Many researchers believe that Herceptin works because it stops tumor cells from growing and causes them to self-destruct through a natural process called programmed cell death, explains first author Julie M. Roda, a graduate research associate in Carson 's laboratory.
But, Roda says, “our findings provide new evidence that Herceptin works at least in part by stimulating NK cells activity, and that IL-21 enhances that action.”
Carson, Roda and their collaborators chose to study IL-21 because the substance is known to activate NK cells and causes them to release substances that attract other immune cells to a tumor site.
This study's findings came from several experiments. First, the scientists exposed NK cells in Petri dishes to both Herceptin and IL-21. This caused the cells to release three to 10 times more of a substance called interferon gamma than would cells exposed to either agent alone.
Interferon gamma is an immune-system signaling agent that causes the NK cells to become more active. It also increases the activity of other immune cells and forces tumor cells to self-destruct.
The researchers then repeated this experiment in mice. They found that animals given both IL-21 and Herceptin-coated tumor cells had nearly three times more interferon gamma in their blood than did animals injected with either of those items alone.
Still another experiment used mice with HER2-positive tumors. When the animals were treated with both the mouse version of Herceptin and IL-21, the tumors shrunk by nearly half compared to those in mice receiving either agent alone.
Last, to test whether the interferon gamma was important for causing the tumors to shrink, the researchers repeated this experiment using mice that cannot make the substance.
The researchers were surprised to find that when interferon gamma was missing, the mouse drug and IL-21 combination had no effect on the tumors.
“We thought if we took out interferon gamma, the NK cells would still be able to kill the tumor cells,” Roda says.
But that didn't happen
“This is very interesting because it suggests that interferon gamma production might be critical to the response to Herceptin, and I believe that we are the first to show this.”
Overall, says Carson , “Our results suggest that IL-21 might enhance the effectiveness of Herceptin, and perhaps similar anticancer drugs.”
Funding from the National Cancer Institute supported this research.
Darrell E. Ward | EurekAlert!
Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction